J Korean Diabetes.  2019 Jun;20(2):92-98. 10.4093/jkd.2019.20.2.92.

Sodium-Glucose Cotransporter 2 Inhibitors for People with Type 1 Diabetes

Affiliations
  • 1Department of Internal Medicine, Yeungnam University College of Medicine, Daegu, Korea. mjs7912@yu.ac.kr

Abstract

Althowgh intensive insulin regimen is the main treatment in people with type 1 diabetes, glucose variability and weight gain remain as challenges for this treatment. Sodium-glucose cotransporter (SGLT) inhibitors (including the SGLT1/2 inhibitors) have emerged as an add-on therapy for insulin treatment in peoples with type 1 diabetes due to their insulin-independent mechanism. Recent clinical trials have consistently reported that SGLT inhibition provides additive benefits in glycemic control, including lower insulin dose and weight loss. However, there is concern that an increase in ketone-related adverse events such as diabetic ketoacidosis is higher in SGLT1/2, as well as SGLT2 inhibitors. Despite safety issues that require further evaluation, SGLT2 inhibitors used with caution may provide an adjunctive therapy in people with type 1 diabetes.

Keyword

Diabetes mellitus; type 1; Diabetic ketoacidosis; Insulin; Sodium-glucose cotransporter-2 inhibitor

MeSH Terms

Diabetes Mellitus
Diabetic Ketoacidosis
Glucose
Insulin
Weight Gain
Weight Loss
Glucose
Insulin
Full Text Links
  • JKD
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
    DB Error: unknown error